Benzinga | Dec 15, 2020 06:10AM EST

SVB Leerink Downgrades Innate Pharma to Market Perform, Lowers Price Target to $5

SVB Leerink analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform to Market Perform and lowers the price target from $7 to $5.